These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 33777757)

  • 21. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
    Nishino M; Ramaiya NH; Hatabu H; Hodi FS
    Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
    Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM
    Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
    House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
    Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of responses to immune checkpoint blockade in advanced melanoma.
    Jacquelot N; Roberti MP; Enot DP; Rusakiewicz S; Ternès N; Jegou S; Woods DM; Sodré AL; Hansen M; Meirow Y; Sade-Feldman M; Burra A; Kwek SS; Flament C; Messaoudene M; Duong CPM; Chen L; Kwon BS; Anderson AC; Kuchroo VK; Weide B; Aubin F; Borg C; Dalle S; Beatrix O; Ayyoub M; Balme B; Tomasic G; Di Giacomo AM; Maio M; Schadendorf D; Melero I; Dréno B; Khammari A; Dummer R; Levesque M; Koguchi Y; Fong L; Lotem M; Baniyash M; Schmidt H; Svane IM; Kroemer G; Marabelle A; Michiels S; Cavalcanti A; Smyth MJ; Weber JS; Eggermont AM; Zitvogel L
    Nat Commun; 2017 Sep; 8(1):592. PubMed ID: 28928380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade.
    Shang J; Han X; Zha H; Tao H; Li X; Yuan F; Chen G; Wang L; Ma J; Hu Y
    Front Oncol; 2021; 11():585271. PubMed ID: 33718140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
    Zhang F; Ferrero M; Dong N; D'Auria G; Reyes-Prieto M; Herreros-Pomares A; Calabuig-Fariñas S; Duréndez E; Aparisi F; Blasco A; García C; Camps C; Jantus-Lewintre E; Sirera R
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34063829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer.
    Grecea M; Soritau O; Dulf D; Ciuleanu TE; Zdrenghea M
    Onco Targets Ther; 2021; 14():5275-5291. PubMed ID: 34848970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.
    McGrail DJ; Pilié PG; Dai H; Lam TNA; Liang Y; Voorwerk L; Kok M; Zhang XH; Rosen JM; Heimberger AB; Peterson CB; Jonasch E; Lin SY
    Sci Transl Med; 2021 Oct; 13(617):eabe6201. PubMed ID: 34705519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
    Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
    J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies.
    Filipovic A; Miller G; Bolen J
    Front Cell Dev Biol; 2020; 8():155. PubMed ID: 32258034
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Kim J; Francis DM; Thomas SN
    Nanomaterials (Basel); 2021 Feb; 11(2):. PubMed ID: 33673289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
    Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ
    Front Immunol; 2020; 11():223. PubMed ID: 32133005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects.
    Bronger H
    Geburtshilfe Frauenheilkd; 2021 Oct; 81(10):1128-1144. PubMed ID: 34629492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finding the hot spot: identifying immune sensitive gastrointestinal tumors.
    De Souza ALPB
    Transl Gastroenterol Hepatol; 2020; 5():48. PubMed ID: 33073043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.
    Zhu N; Weng S; Wang J; Chen J; Yu L; Fang X; Yuan Y
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3021-3036. PubMed ID: 31617075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity.
    Zhang Z; Rafei-Shamsabadi D; Lehr S; Buettner N; Diehl R; Huzly D; Pinato DJ; Thimme R; Meiss F; Bengsch B
    J Transl Med; 2022 Dec; 20(1):582. PubMed ID: 36503532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.